Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026
Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Drug

Kelun Pharma’s SKB264 Advances to Phase II Study for NSCLC

Fineline Cube Nov 16, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody drug conjugate...

Company

Gracell’s FasTCAR Platform Wins Fierce Life Sciences Innovation Award

Fineline Cube Nov 16, 2022

China-based Gracell Biotechnologies Inc’s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this...

Company Deals

Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines

Fineline Cube Nov 16, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with...

Company Deals

Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China

Fineline Cube Nov 16, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with...

Company

Sirnaomics Announces Key Executive Promotions Effective November 15

Fineline Cube Nov 16, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite,...

Company Drug

Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study

Fineline Cube Nov 16, 2022

China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled,...

Company Drug

Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631

Fineline Cube Nov 16, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals...

Company Drug

Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies

Fineline Cube Nov 16, 2022

Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2...

Company Drug

CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation

Fineline Cube Nov 16, 2022

The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation...

Company Drug

Betta Pharmaceuticals’ BPI-D0316 Accepted for NMPA Review for NSCLC Adjuvant Therapy

Fineline Cube Nov 16, 2022

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that its clinical trial filing for...

Company Drug

Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study

Fineline Cube Nov 16, 2022

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...

Company Deals

Junovabio Secures Pre-Series A Funding for Tumor Molecular Diagnosis

Fineline Cube Nov 16, 2022

Junovabio, a Shanghai-based molecular diagnostics specialist, has reportedly raised “tens of millions” of renminbi in...

Company Deals

Lupeng Pharma Raises USD 35 Million in Pre-Series B Financing Round

Fineline Cube Nov 16, 2022

China-based Lupeng Pharmaceutical Ltd has reportedly raised USD 35 million in Phase 2 of a...

Company Drug

Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa

Fineline Cube Nov 15, 2022

Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...

Company Deals

Silk Round Fund and INA Invest in Indonesian Pharma Companies

Fineline Cube Nov 15, 2022

The Chinese state-owned Silk Round Fund (SRF) and Indonesia’s sovereign fund INA have reportedly agreed...

Company Drug

LaNova Medicines Gets NMPA Approval for LM-305 Clinical Study

Fineline Cube Nov 15, 2022

Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from...

Company Drug

Everest Medicines’ Nefecon NDA Accepted for IgA Nephropathy in China

Fineline Cube Nov 15, 2022

China-based biotech Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has...

Company

CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs

Fineline Cube Nov 15, 2022

CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of...

Company Medical Device

Hotgen Receives NMPA Approval for HBV RNA Assay Kit

Fineline Cube Nov 15, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced that it has received marketing approval...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity

Fineline Cube Nov 15, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...

Posts pagination

1 … 577 578 579 … 643

Recent updates

  • Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline
  • NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines
  • Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib
  • NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications
  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Company

Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib

Policy / Regulatory

NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.